We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 6.70 | 7.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 6.85 | GBX |
Venn Life Sciences (VENN) Share Charts1 Year Venn Life Sciences Chart |
|
1 Month Venn Life Sciences Chart |
Intraday Venn Life Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/7/2019 | 12:10 | one to follow for great potential is VENN | 1,484 |
| 14/3/2019 | 16:35 | Venn Life Sciences | 38 |
| 24/3/2016 | 19:04 | Venn Life Sciences......rapid growth and potential ! | 294 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/6/2019 11:07 by yump Apparently VENN was 'under-capitalised'.That's why their revenue dropped, although there isn't any explanation of exactly how that process worked. No quotes of 'this that and the other potential client wouldn't give us the contract because our balance sheet looked rubbish'. Believe that and you'll believe anything. 'Orphan drugs': the ones nobody will touch because they require government or other subsidy (new shareholders ??) to make them commercially viable. |
Posted at 21/6/2019 11:00 by yump Much more to come because Winnifroth has shares. I wonder what price they were bought at... |
Posted at 13/6/2019 19:37 by aishah Venn Life Sciences – shares restored at a massive premium… but much more to come |
Posted at 13/6/2019 19:31 by jpuff So what's the verdict on the corporate action? (Given I'm an existing long suffering holder of Venn)? |
Posted at 11/6/2019 07:19 by cocker I agree and although it has served me well Buywell I still am not 100% convinced that the constant dilutions are in the interest of shareholders. I sold my remaining few shares of 35k in Venn 1st thing as TU wasn't impressive |
Posted at 10/5/2019 18:40 by cocker Wait for it, share placing @ 50% discount to current share price Trying to buy its self out of trouble with another related transaction. Richardson if you're reading this, you really are a useless C@@T & anyone wanting to invest here most be ready for the lunatic asylum. |
Posted at 10/5/2019 06:45 by jpuff AIM Suspension - Venn Life Sciences Holdings PlcSource: UK Regulatory (RNS & others)TIDMVENNRNS Number : 5713YAIM10 May 2019NOTICE10/05/2019 7:30amTEMPORARY SUSPENSION OF TRADING ON AIMVENN LIFE SCIENCES HOLDINGS PLCAt the request of the Company trading on AIM for the under-mentioned securities has been temporarily suspended from 10/05/2019 7:30am, pending publication of an admission document and an announcement.ORDINAR |
Posted at 25/1/2019 21:40 by cocker This company has gone from 20p+ - 1.5p in a very short time because it has failed miserably. The past maybe no guide to the future, but with Richardson's guidence Venn has almost exhausted every financial avenue available to them, thus why the last one in December is with private individuals with a 10% coupon. Related transactions which are still promenant with SKIN and it seems a business model that is flawed, it remains a very risky punt. I understand the attraction of bottom fishing and if it works for you, then well done. But, when the share price has risen 0.5p let's not get carried away, Venn is being run for the purpose of lining its directors pockets & until they prove otherwise, I won't be investing. |
Posted at 11/12/2018 11:59 by rivaldo For the record from the analyst at Davy this morning...."DAVY VIEW Venn’s strategic collaboration with Open Orphan should feed through into new business opportunities in the high growth orphan (rare) disease market – an area of strong focus for Venn. The principles of Open Orphan will be joining Venn’s Board – Professor Brendan Buckley was previously Chief Medical Officer for ICON and brings a wealth of experience and a business network that should benefit Venn. The new financing consisting of £1m loan notes means more capital is available for Venn to invest in the business and possible M&A. Our FY 2018 and FY 2019 revenue forecasts are now €13.8m and €16.5m respectively. Our FY 2018 and FY 2019 EBITDA forecasts are -€0.5m and €0.4m respectively." |
Posted at 22/8/2017 08:48 by rivaldo Cheers basem, appreciated.Personally I follow the fundamentals, and they're telling me that VENN is fundamentally undervalued. That will be the case even if VENN fails to achieve Hybridan's forecast £1.27m adjusted PBT, which I'm not sure they will. If VENN were to achieve only 50% of that - say a £600k PBT - if you combine that with the almost €3m cash pile, the investment in SKIN and the value of the core business as outlined in my post 1005 then VENN is worth considerably more than the current share price. In a small-cap like this, one or two larger sellers can easily drive the share price down to silly levels given the propensity of others to follow them out on a drifting share price, the hitting of stop-losses etc. I believe that's what happened here. As spooky says, it looks like the share price has hit a bottom and is starting to lift itself off that bottom now. The solid H1 update and the confidence for the full year should continue this into and onwards from the H1 results next month. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
